Please login to the form below
kinase inhibitor
This page shows the latest kinase inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck signs separate agreements with Seattle Genetics for two cancer drugs
PD-1 inhibitor Keytruda (pembrolizumab) following the new agreement. ... In a separate agreement, Seattle Genetics has granted Merck an exclusive license to commercialise Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, in Asia, the Middle
Latest news
-
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... Compared to treatment with
-
RedHill Biopharma advances phase 2/3 COVID-19 programme
Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-inflammatory and anti-viral activities.
-
Servier and Oncodesign reach first milestone in Parkinson’s partnership
Oncodesign’s Nanocyclix platform uses a macrocyclisation chemical methodology to generate kinase inhibitor candidates "based on shape complementarity in the ATP binding site" of kinase enzymes. ... After the selection a few weeks ago of our first
-
NICE turns down Keytruda/Inlyta combo for kidney cancer
However, the long-term benefit of checkpoint inhibitor Keytruda (pembrolizumab) and tyrosine kinase inhibitor Inlyta (axitinib) in these patients is uncertain, which makes it hard to estimate its cost-effectiveness, according ... The results outperformed
-
Lilly posts higher-than-expected profit as new drugs lift outlook
This includes TGF-beta R1 kinase inhibitor galunisertib, which had been in trial in lung and liver cancer.
More from news
Approximately 0 fully matching, plus 164 partially matching documents found.
Latest Intelligence
-
AI: the smart money is on the smart thinking
Using machine learning, a small team of four researchers were able to identify an initial 370 kinase inhibitors, and then quickly narrow this down to the six most likely to work – ... Using GENTRL, the company was able to design a novel DDR1 kinase
-
Can protein degraders unlock ‘undruggable’ drug targets?
Some groups are focusing on SNIPERs – an acronym for Specific and Non-genetic Inhibitor of apoptosis protein-dependent Protein Erasers. – ... These compounds could be used to tackle resistance to kinase inhibitor drugs, for example.
-
Deal Watch January 2018
The headline value contains significant sales milestones linked to performance of Impact's lead phase III stage asset fedratinib, an oral JAK2 kinase inhibitor in development for the treatment of myelofibrosis ... Acquisition company - remaining 90%. 9
-
Deal Watch September 2016
No financial terms were disclosed. Genentech signed an exclusive licence [global excluding South Korea] with Hanmi Pharmaceutical to develop and market HM95573, a pan-RAF inhibitor. ... 1, 000+. Hanmi / Genentech. Licence. HM95573, a selective
-
Deal Watch June 2016
acquisition assets. 350. CrystalGenomics/ Aptose Biosciences. CG026806 inhibitor of Bruton's tyrosine kinase, FMS-like tyrosine kinase 3 and Aurora kinases (preclinical). † ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe.
More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.
Latest appointments
-
Akinion appoints Dr Richard Jones as CEO
In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently
-
Creabilis names Catherine Moukheibir as chairman of the board
Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
Iguazu
Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
